HP
OPNT

HealthInvest Partners’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

HealthInvest Partners’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-210,000
Closed -$2.26M – 55
2022
Q3 		$2.26M Hold
210,000
– – 4.77% 9
2022
Q2 		$2.52M Buy
210,000
+192,000
+1,067% +$3.1M 5.8% 11
2022
Q1 		$386K Buy
+18,000
New +$477K 0.61% 12

Other funds holding OPNT

WSL
Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return
ACA
Apis Capital Advisors New York $1.03B AUM 383.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
NYLIM
New York Life Investment Management New York $14.3B AUM 34.42% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
RA
Ramius Advisors New York $95.2M AUM 7.33% 1-Year Est. Return

HealthInvest Partners's OPNT Position: Q4 2022 in Review

HealthInvest Partners sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q4 2022, closing a stake of 210,000 shares — an estimated $2.26M sold.

HealthInvest Partners first reported a position in OPNT in Q1 2022 and held it in 3 quarters. The position peaked at $2.52M in Q2 2022. 36 funds tracked by Wall St. Rank hold OPNT as of Q4 2022.

  • HealthInvest Partners reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • HealthInvest Partners sold 210,000 Opiant Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $2.26M.
  • HealthInvest Partners first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
  • HealthInvest Partners's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $2.52M in Q2 2022.
  • 36 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on HealthInvest Partners's 13F filing for Q4 2022, filed 14 Feb 2023.